Key Takeaways ISRG's Q3 revenues rose nearly 20%, powered by da Vinci 5 and rapid Ion and SP platform expansion.BSX posted 15% organic growth as WATCHMAN and FARAPULSE drove gains in electrophysiology and cardiology.Both firms hold Zacks Rank #2 (Buy), with BSX seen as more attractively valued versus the industry and ISRG.Two of medtech’s most closely watched names — Intuitive Surgical (ISRG) and Boston Scientific (BSX) — reported strong third-quarter results that underline their very different paths to gro ...